vs
Side-by-side financial comparison of HALOZYME THERAPEUTICS, INC. (HALO) and WESBANCO INC (WSBC). Click either name above to swap in a different company.
HALOZYME THERAPEUTICS, INC. is the larger business by last-quarter revenue ($451.8M vs $257.2M, roughly 1.8× WESBANCO INC). WESBANCO INC runs the higher net margin — 34.5% vs -31.3%, a 65.8% gap on every dollar of revenue. Over the past eight quarters, HALOZYME THERAPEUTICS, INC.'s revenue compounded faster (51.9% CAGR vs 31.9%).
Halozyme Therapeutics, Inc. is an American biotechnology company. It develops oncology therapies designed to target the tumor microenvironment.
WesBanco, Inc., is a bank holding company headquartered in Wheeling, West Virginia, United States. It has over 200 branches in West Virginia, Ohio, Western Pennsylvania, Kentucky, Maryland, and Southern Indiana.
HALO vs WSBC — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $451.8M | $257.2M |
| Net Profit | $-141.6M | $88.6M |
| Gross Margin | 82.6% | — |
| Operating Margin | -20.6% | — |
| Net Margin | -31.3% | 34.5% |
| Revenue YoY | 51.6% | — |
| Net Profit YoY | -203.3% | 54.4% |
| EPS (diluted) | $-1.13 | $0.88 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $257.2M | ||
| Q4 25 | $451.8M | $265.6M | ||
| Q3 25 | $354.3M | $261.6M | ||
| Q2 25 | $325.7M | $260.7M | ||
| Q1 25 | $264.9M | $193.2M | ||
| Q4 24 | $298.0M | $162.9M | ||
| Q3 24 | $290.1M | $150.8M | ||
| Q2 24 | $231.4M | $147.9M |
| Q1 26 | — | $88.6M | ||
| Q4 25 | $-141.6M | $91.1M | ||
| Q3 25 | $175.2M | $83.6M | ||
| Q2 25 | $165.2M | $57.4M | ||
| Q1 25 | $118.1M | $-9.0M | ||
| Q4 24 | $137.0M | $49.6M | ||
| Q3 24 | $137.0M | $37.3M | ||
| Q2 24 | $93.2M | $28.9M |
| Q1 26 | — | — | ||
| Q4 25 | 82.6% | — | ||
| Q3 25 | 84.4% | — | ||
| Q2 25 | 85.8% | — | ||
| Q1 25 | 81.7% | — | ||
| Q4 24 | 85.9% | — | ||
| Q3 24 | 83.0% | — | ||
| Q2 24 | 82.9% | — |
| Q1 26 | — | — | ||
| Q4 25 | -20.6% | 43.2% | ||
| Q3 25 | 61.5% | 39.5% | ||
| Q2 25 | 62.2% | 27.2% | ||
| Q1 25 | 53.4% | -5.0% | ||
| Q4 24 | 58.9% | 38.0% | ||
| Q3 24 | 56.3% | 29.7% | ||
| Q2 24 | 50.7% | 23.7% |
| Q1 26 | — | 34.5% | ||
| Q4 25 | -31.3% | 34.3% | ||
| Q3 25 | 49.5% | 31.9% | ||
| Q2 25 | 50.7% | 22.0% | ||
| Q1 25 | 44.6% | -4.7% | ||
| Q4 24 | 46.0% | 30.5% | ||
| Q3 24 | 47.2% | 24.7% | ||
| Q2 24 | 40.3% | 19.5% |
| Q1 26 | — | $0.88 | ||
| Q4 25 | $-1.13 | $0.97 | ||
| Q3 25 | $1.43 | $0.84 | ||
| Q2 25 | $1.33 | $0.57 | ||
| Q1 25 | $0.93 | $-0.15 | ||
| Q4 24 | $1.06 | $0.72 | ||
| Q3 24 | $1.05 | $0.54 | ||
| Q2 24 | $0.72 | $0.44 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $133.8M | — |
| Total DebtLower is stronger | $2.1B | — |
| Stockholders' EquityBook value | $48.8M | $4.1B |
| Total Assets | $2.5B | $27.5B |
| Debt / EquityLower = less leverage | 43.89× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $133.8M | $956.1M | ||
| Q3 25 | $419.7M | $1.0B | ||
| Q2 25 | $61.9M | $1.2B | ||
| Q1 25 | $176.3M | $1.1B | ||
| Q4 24 | $115.8M | $568.1M | ||
| Q3 24 | $154.3M | $620.9M | ||
| Q2 24 | $187.9M | $486.8M |
| Q1 26 | — | — | ||
| Q4 25 | $2.1B | — | ||
| Q3 25 | $1.5B | — | ||
| Q2 25 | $1.5B | — | ||
| Q1 25 | $1.5B | — | ||
| Q4 24 | $1.5B | — | ||
| Q3 24 | $1.5B | — | ||
| Q2 24 | $1.5B | — |
| Q1 26 | — | $4.1B | ||
| Q4 25 | $48.8M | $4.0B | ||
| Q3 25 | $503.9M | $4.1B | ||
| Q2 25 | $332.7M | $3.8B | ||
| Q1 25 | $482.3M | $3.8B | ||
| Q4 24 | $363.8M | $2.8B | ||
| Q3 24 | $452.7M | $2.8B | ||
| Q2 24 | $289.4M | $2.5B |
| Q1 26 | — | $27.5B | ||
| Q4 25 | $2.5B | $27.7B | ||
| Q3 25 | $2.2B | $27.5B | ||
| Q2 25 | $2.1B | $27.6B | ||
| Q1 25 | $2.2B | $27.4B | ||
| Q4 24 | $2.1B | $18.7B | ||
| Q3 24 | $2.1B | $18.5B | ||
| Q2 24 | $2.0B | $18.1B |
| Q1 26 | — | — | ||
| Q4 25 | 43.89× | — | ||
| Q3 25 | 3.00× | — | ||
| Q2 25 | 4.54× | — | ||
| Q1 25 | 3.13× | — | ||
| Q4 24 | 4.14× | — | ||
| Q3 24 | 3.32× | — | ||
| Q2 24 | 5.19× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $219.0M | — |
| Free Cash FlowOCF − Capex | $217.6M | — |
| FCF MarginFCF / Revenue | 48.2% | — |
| Capex IntensityCapex / Revenue | 0.3% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $644.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $219.0M | $290.4M | ||
| Q3 25 | $178.6M | $116.9M | ||
| Q2 25 | $99.7M | $105.0M | ||
| Q1 25 | $154.2M | $-26.4M | ||
| Q4 24 | $178.5M | $211.0M | ||
| Q3 24 | $115.4M | $60.7M | ||
| Q2 24 | $55.8M | $18.2M |
| Q1 26 | — | — | ||
| Q4 25 | $217.6M | $280.0M | ||
| Q3 25 | $175.6M | $114.9M | ||
| Q2 25 | $98.1M | $98.3M | ||
| Q1 25 | $153.3M | $-30.7M | ||
| Q4 24 | $175.4M | $200.7M | ||
| Q3 24 | $113.9M | $56.9M | ||
| Q2 24 | $53.2M | $17.3M |
| Q1 26 | — | — | ||
| Q4 25 | 48.2% | 105.4% | ||
| Q3 25 | 49.6% | 43.9% | ||
| Q2 25 | 30.1% | 37.7% | ||
| Q1 25 | 57.9% | -15.9% | ||
| Q4 24 | 58.9% | 123.2% | ||
| Q3 24 | 39.3% | 37.7% | ||
| Q2 24 | 23.0% | 11.7% |
| Q1 26 | — | — | ||
| Q4 25 | 0.3% | 3.9% | ||
| Q3 25 | 0.9% | 0.8% | ||
| Q2 25 | 0.5% | 2.6% | ||
| Q1 25 | 0.4% | 2.2% | ||
| Q4 24 | 1.0% | 6.3% | ||
| Q3 24 | 0.5% | 2.5% | ||
| Q2 24 | 1.1% | 0.6% |
| Q1 26 | — | — | ||
| Q4 25 | — | 3.19× | ||
| Q3 25 | 1.02× | 1.40× | ||
| Q2 25 | 0.60× | 1.83× | ||
| Q1 25 | 1.31× | — | ||
| Q4 24 | 1.30× | 4.25× | ||
| Q3 24 | 0.84× | 1.63× | ||
| Q2 24 | 0.60× | 0.63× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HALO
| Royalty | $258.0M | 57% |
| Products | $122.7M | 27% |
| Proprietary Products Sales | $59.6M | 13% |
| Device Partnered Products | $12.9M | 3% |
WSBC
| Net Interest Income | $215.4M | 84% |
| Noninterest Income | $41.8M | 16% |
